Sharemaestro company-news research for Revolution Medicines Inc (RVMD), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Measured evidence
Company news sentiment
Latest RVMD news and sentiment
Revolution Medicines Inc
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score55Neutral is 50
Balanced news tone
39/100 evidence confidence
91% direct company focus
68 current stories across 20 publishers
Current company news
Balanced news tone
The score uses 68 current company stories from 20 publishers.
Observed headline tone60/100
→
Published 30-day score55/100
Latest source headline
Did First RASONQUE (daraxonrasib) Approval and NEJM Data Just Shift Revolution Medicines' (RVMD) Investment Narrative?
simplywall.st · 07 Sep 2026 11:33
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
68 current stories are mapped specifically to RVMD.
The score uses 20 publishers rather than depending on one outlet.
The current stories agree at 86/100.
What limits the score
No major limit stands out.
55/100
News scoreBalanced news tone
39/100
Confidencethin evidence
91%/100
Company news68 company stories
86/100
Story agreement14/100 difference
News history
Daily score and story count over 30 days
09 Aug24 Aug07 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence23
1.126 after freshness weightingSource breadth100
20 independent publishersCompany relevance91
share tied directly to this companyFreshness33
recency-weighted evidenceAgreement86
how closely stories agreePublisher mix89
less reliance on one publisherPrice and news history
Weekly price and news-score history
News tone and price action are not far from neutral.
26 completed price weeks26 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Mar09 Jun04 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
04 Sep 202657USD 210.02+1.0%
28 Aug 202656USD 207.88-0.8%
21 Aug 202652USD 209.46+2.8%
14 Aug 202653USD 203.71-0.7%
07 Aug 202654USD 205.15+9.4%
31 Jul 202658USD 187.53-0.9%
24 Jul 202658USD 189.23+1.6%
17 Jul 202651USD 186.16-0.4%
News subjects
What is shaping the score
Earnings4220 stories · 29%
Market update5119 stories · 28%
Deals and strategy5713 stories · 19%
Regulatory and legal6211 stories · 16%
Analyst action645 stories · 7%
Source mix
Where the evidence comes from
finance.yahoo.com628 stories · 12%
MarketBeat518 stories · 12%
Stock Titan508 stories · 12%
simplywall.st625 stories · 7%
Simply Wall St.483 stories · 4%
Simply Wall Street523 stories · 4%
TradingView503 stories · 4%
Recurring subjects
Subjects appearing most often
Life Sciences36Financial Markets24Earnings17Biotech14Finance11Fda Approval10Clinical Trials10Oncology8Pharma6Balance Sheet5
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
23 Jun50 neutral07 Sep 19:56
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 07 Sep 19:56 | 55 | +0 | 36/100 (-4) | 69 (-2) | Measured |
| 05 Sep 23:59 | 55 | -2 | 40/100 (+1) | 71 (-2) | Measured |
| 04 Sep 23:59 | 57 | +0 | 39/100 (-6) | 73 (-6) | Measured |
| 01 Sep 23:59 | 57 | +1 | 45/100 (-1) | 79 (-4) | Measured |
| 29 Aug 23:59 | 56 | +0 | 46/100 (-4) | 83 (-2) | Measured |
| 28 Aug 23:59 | 56 | +2 | 50/100 (+8) | 85 (+3) | Measured |
| 27 Aug 23:59 | 54 | +2 | 42/100 (+1) | 82 (+2) | Measured |
| 26 Aug 23:59 | 52 | +7 | 41/100 (+9) | 80 (+3) | Measured |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#1—Not directional
simplywall.stDirect company coverageScored from headline
Did First RASONQUE (daraxonrasib) Approval and NEJM Data Just Shift Revolution Medicines' (RVMD) Investment Narrative?
- Published
- 07 Sep 2026 11:33
- News subject
- Regulatory and legal
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 0.3d old
- Duplicates
- 1 consolidated
#241Tone
Simply Wall St.Direct company coverageStored article
Revolution Medicines (RVMD) Stock Looks Overvalued Even After Its Drug Approval
Revolution Medicines has delivered very large share price gains over the past few years, while broad valuation checks currently suggest the stock leans expensive rather than offering clear value. For investors, the question is how to balance that strong share price history against what the recent valuation signals are implying today. Over the past 5 years, Revolution Medicines has returned about 6x, which sets a high bar for any further upside from here. The recent FDA approval for Rasonque in metastatic pancreatic cancer can support expectations for future cash generation, while the high list
Balance SheetBiotechFda ApprovalHealthcareShare PriceShareholder
- Published
- 05 Sep 2026 14:13
- News subject
- Regulatory and legal
- Why this score
- Negative valuation view
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 47/100
- 30-day weight
- 10.5% of the score · 2.2d old
- Duplicates
- 2 consolidated
#357Tone
Simply Wall St.Direct company coverageStored article
Revolution Medicines (RVMD) Wins FDA Nod While Cancer Study Lands In Leading Journal
Revolution Medicines (NasdaqGS:RVMD) reported US FDA approval of RASONQUE for adults with previously treated metastatic pancreatic adenocarcinoma, the first broad RAS targeted therapy for this cancer type. RASONQUE is the first approved therapy from a new class of RAS(ON) multi selective inhibitors aimed at tumors driven by RAS mutations. Phase 1/2 clinical data for RASONQUE in RAS mutant non small cell lung cancer were published in the New England Journal of Medicine, providing independent peer reviewed visibility on its clinical profile. The twin milestones add a new option for certain patie
BiotechClinical TrialsFda ApprovalOncology
- Published
- 05 Sep 2026 05:06
- News subject
- Regulatory and legal
- Why this score
- Fda Approval
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 43/100
- 30-day weight
- 8.6% of the score · 2.6d old
- Duplicates
- 1 consolidated
#457Tone
Insider MonkeyDirect company coverageStored article
Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough?
Revolution Medicines, Inc. (NASDAQ:RVMD) received FDA approval for Rasonque, or daraxonrasib, following an expedited review. The once-daily oral RAS inhibitor is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. Revolution Medicines, Inc. (NASDAQ:RVMD) set a wholesale acquisition cost (WAC) of $39,800 for a 30-day supply. Twelve 30-day supplies would total $477,600 at WAC before discounts, rebates, or assistance. Rasonque is available in the United States, with (ON)Path offe
Fda ApprovalOncologyPharma
- Published
- 04 Sep 2026 17:22
- News subject
- Deals and strategy
- Why this score
- Fda Approval
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 42/100
- 30-day weight
- 5.9% of the score · 3.1d old
- Duplicates
- 1 consolidated
#5—Not directional
MarketBeatDirect company coverageScored from headline
Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Published
- 04 Sep 2026 17:15
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 3.1d old
- Duplicates
- 1 consolidated
#6—Not directional
ZacksDirect company coverageStored article
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Revolution Medicines, Inc. (RVMD). Shares have added about 6.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Revolution Medicines due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Q2 Loss Wider Than Expected, Sales Nil Revolution Medicines reported an adjusted loss of $2.34 per share in the sec
BiotechConsensus EstimateEarningsEarnings ReleaseEarnings ReportEstimate Revisions
- Published
- 04 Sep 2026 15:30
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 3.2d old
- Duplicates
- 2 consolidated
#758Tone
WSJDirect company coverageStored article
Why Revolution Medicines, the Drugmaker Behind a Pancreatic Cancer Breakthrough, Stayed Independent
Revolution Medicines, a biotech company, chose to remain independent despite takeover interest, a decision that proved successful with the FDA approval of its pancreatic cancer pill, Rasonque (daraxonrasib). The company, which previously had no drugs on the market, focused on promising research that has now led to a significant breakthrough for adults with metastatic pancreatic cancer.
Life SciencesMergers And Acquisitions
- Published
- 01 Sep 2026 22:25
- News subject
- Deals and strategy
- Why this score
- Fda Approval
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 45/100
- 30-day weight
- 12% of the score · 5.9d old
- Duplicates
- 1 consolidated
#870Tone
simplywall.stDirect company coverageScored from headline
Revolution Medicines (RVMD) Could Be 7% Below Fair Value On FDA Approval Of RASONQUE
- Published
- 01 Sep 2026 08:33
- News subject
- Regulatory and legal
- Why this score
- Fda Approval
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 56/100
- 30-day weight
- 10.2% of the score · 6.5d old
- Duplicates
- 1 consolidated
#9—Not directional
TheStreetDirect company coverageStored article
Patients with the deadliest cancer finally have something that works
For decades, a pancreatic cancer diagnosis came with almost no good options. The disease is usually caught late, spreads fast, and resists most treatments. Patients and their families were often left with months, not years. That grim picture just changed. On Aug. 26, the U.S. Food and Drug Administrationapproved Rasonque daraxonrasib, a once-daily pill from Revolution Medicines (RVMD). It is the first broad RAS-targeted medicine cleared for adults with metastatic pancreatic cancer who have already had chemotherapy. For investors, the approval turns a research-stage company into one with a prod
Balance SheetBiotechDrug ApprovalEarnings ReportFda ApprovalOncology
- Published
- 29 Aug 2026 17:07
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.1d old
- Duplicates
- 1 consolidated
#1057Tone
Insider MonkeyDirect company coverageStored article
Revolution Medicines (RVMD) Made Pancreatic-Cancer History. At $47B Valuation, the Market Already Assumed It
Revolution Medicines, Inc. (NASDAQ:RVMD) touched an all-time high above $224 on August 27, 2026, following FDA approval of Rasonque (daraxonrasib) – the first broad RAS-targeted therapy cleared for metastatic pancreatic cancer. Creating a milestone, the approval came roughly five weeks after filing under the agency's national priority voucher. The pivotal RASolute 302 trial nearly doubled median overall survival, to 13.2 months from 6.7 on chemotherapy. While the clinical benefit is substantial, a $47 billion valuation suggests the market had already priced in this success.Revolution Medicines
Clinical TrialsFda ApprovalInstitutional InvestorsOncologyPharmaValuation
- Published
- 28 Aug 2026 20:54
- News subject
- Regulatory and legal
- Why this score
- Fda Approval
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 35/100
- 30-day weight
- 3.9% of the score · 10.0d old
- Duplicates
- 1 consolidated
#1163Tone
MT NewswiresDirect company coverageStored article
Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says
Revolution Medicines (RVMD) should post "strong launch numbers" for pancreatic cancer drug Rasonque PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in
BiotechHealthcarePharma
- Published
- 28 Aug 2026 16:18
- News subject
- Analyst action
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 33/100
- 30-day weight
- 0.8% of the score · 10.2d old
- Duplicates
- 1 consolidated
#1268Tone
MT NewswiresDirect company coverageScored from headline
UBS Adjusts Revolution Medicines Price Target to $265 From $220, Maintains Buy Rating
- Published
- 28 Aug 2026 13:33
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 42/100
- 30-day weight
- 1.2% of the score · 10.3d old
- Duplicates
- 1 consolidated
#1367Tone
Motley FoolDirect company coverageScored from headline
Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?
- Published
- 28 Aug 2026 11:27
- News subject
- Regulatory and legal
- Why this score
- Contract or approval won
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 50/100
- 30-day weight
- 6.5% of the score · 10.4d old
- Duplicates
- 1 consolidated
#14—Not directional
Simply Wall St.Direct company coverageStored article
Revolution Medicines (RVMD) After RASONQUE Approval Is The Valuation Story Still Intact
Revolution Medicines (RVMD) is in focus after the U.S. Food and Drug Administration approved RASONQUE, a once daily oral RAS inhibitor for certain adults with metastatic pancreatic adenocarcinoma following prior treatment. Revolution Medicines' share price has reacted strongly around these developments, with a 1-month share price return of 22.24% and a 3-month share price return of 40.43% helping lift the stock to US$221.15. The 1-year total shareholder return is also very large, indicating powerful positive momentum over both shorter and longer periods. Scan the market for other oncology stoc
BiotechFda ApprovalOncologyRevenue GrowthShare PriceShareholder
- Published
- 28 Aug 2026 06:18
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.6d old
- Duplicates
- 1 consolidated
#1557Tone
BioPharma DiveDirect company coverageStored article
Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say
Revolution Medicines' new pancreatic cancer drug, Rasonque, is projected to become a blockbuster with sales potentially reaching $15.1 billion by 2034 for pancreatic cancer alone, and up to $20.8 billion with additional cancer approvals. This optimistic forecast is driven by its higher-than-expected list price of $39,800 per month and a broad FDA approval that allows for flexible use, potentially even as a first-line treatment. Analysts are calling its launch "transformative/historic" due to its scientific breakthrough nature and ability to extend survival in a deadly cancer.
Life Sciences
- Published
- 28 Aug 2026 05:36
- News subject
- Market update
- Why this score
- Fda Approval
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 29/100
- 30-day weight
- 0.2% of the score · 10.6d old
- Duplicates
- 1 consolidated
#1667Tone
simplywall.stDirect company coverageScored from headline
Revolution Medicines (RVMD) Wins FDA Approval For Metastatic Pancreatic Cancer Drug
- Published
- 28 Aug 2026 01:41
- News subject
- Regulatory and legal
- Why this score
- Contract or approval won
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 49/100
- 30-day weight
- 6.2% of the score · 10.8d old
- Duplicates
- 1 consolidated
#1772Tone
BioSpaceDirect company coverageStored article
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
The U.S. FDA has approved Revolution Medicines' RASONQUE (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma, marking the first broad RAS-targeted medicine for this challenging cancer. The approval is based on the Phase 3 RASolute 302 trial, where RASONQUE significantly reduced the risk of death by 60% and demonstrated improved overall survival and quality of life compared to chemotherapy. The drug is now available in the U.S. and represents a monumental step forward in treating RAS-addicted cancers.
Clinical TrialsFda ApprovalFinanceLife SciencesOncologyPancreatic Cancer
- Published
- 27 Aug 2026 22:49
- News subject
- Regulatory and legal
- Why this score
- Contract or approval won
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 51/100
- 30-day weight
- 7% of the score · 10.9d old
- Duplicates
- 1 consolidated
#18—Not directional
finance.yahoo.comDirect company coverageStored article
RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer
Revolution Medicines RVMD announced that the FDA has approved its RAS inhibitor daraxonrasib for previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The drug will be marketed under the brand name Rasonque. Why the Approval Is a Big Deal for RVMD The approval marks a major inflection point for Revolution Medicines, making Rasonque the company's first marketed product and transforming it from a clinical-stage biotech into a commercial-stage oncology company. The FDA's decision is supported by data from the phase III RASolute 302 study, which met all its primary a
BiotechClinical TrialsFda ApprovalOncologyPharma
- Published
- 27 Aug 2026 17:00
- News subject
- Deals and strategy
- Why this score
- Contract or approval won
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.1d old
- Duplicates
- 1 consolidated
#1961Tone
finance.yahoo.comDirect company coverageStored article
Revolution Medicines' Rasonque Label Expands Commercial Opportunity, Oppenheimer Says
Revolution Medicines (RVMD) receiving a broader-than-expected Food and Drug Administration label for PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in
- Published
- 27 Aug 2026 16:21
- News subject
- Analyst action
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 31/100
- 30-day weight
- 0.5% of the score · 11.1d old
- Duplicates
- 1 consolidated
#20—Not directional
The New York TimesDirect company coverageStored article
F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer
The FDA has approved a new drug, daraxonrasib, made by Revolution Medicines, for advanced pancreatic cancer. The drug, sold as Rasonque, is taken as two pills a day and has shown significant improvement in life expectancy, doubling it in clinical trials for patients with metastatic pancreatic cancer who have already undergone chemotherapy. While not a cure, it marks a substantial advancement in treating a historically challenging disease, with a monthly sticker price of $39,800, largely expected to be covered by insurance.
Life Sciences
- Published
- 26 Aug 2026 22:49
- News subject
- Market update
- Why this score
- Contract or approval won
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.9d old
- Duplicates
- 1 consolidated
#21—Not directional
simplywall.stDirect company coverageScored from headline
What Revolution Medicines (RVMD)'s RASONQUE Pancreatic Cancer Focus Means For Shareholders
- Published
- 26 Aug 2026 21:38
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.9d old
- Duplicates
- 1 consolidated
#2267Tone
finance.yahoo.comDirect company coverageStored article
Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock.
Daraxonrasib, the pill touted by a former member of Congress and cancer patient as a ‘miracle drug,’ has been granted approval in patients with pancreatic adenocarcinoma. Continue Reading
Fda ApprovalHealthcarePharma
- Published
- 26 Aug 2026 16:44
- News subject
- Regulatory and legal
- Why this score
- Contract or approval won
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 45/100
- 30-day weight
- 3.8% of the score · 12.1d old
- Duplicates
- 1 consolidated
#2370Tone
ts2.techDirect company coverageScored from headline
Rasonque FDA Approval Lifts Revolution Medicines Stock 0.8% at $45.7 Billion Valuation
- Published
- 26 Aug 2026 16:22
- News subject
- Regulatory and legal
- Why this score
- Fda Approval
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 51/100
- 30-day weight
- 5.8% of the score · 12.1d old
- Duplicates
- 1 consolidated
#2475Tone
GuruFocusDirect company coverageScored from headline
Revolution Medicines (RVMD) Gains FDA Approval for Rasonque, Sha
- Published
- 26 Aug 2026 15:50
- News subject
- Regulatory and legal
- Why this score
- Fda Approval
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 57/100
- 30-day weight
- 6.7% of the score · 12.2d old
- Duplicates
- 1 consolidated
#2557Tone
NAI500Direct company coverageScored from headline
Billionaire Loads Up on Revolution Medicines, the Upside Could Be More Than 7%
- Published
- 26 Aug 2026 08:45
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 29/100
- 30-day weight
- <0.1% of the score · 12.5d old
- Duplicates
- 1 consolidated
#26—Not directional
MoomooDirect company coverageStored article
Revolution Medicines(RVMD.US) Officer Sells US$17.99 Million in Common Stock
An officer at Revolution Medicines (RVMD.US) has sold common stock totaling US$17.99 million. This transaction indicates a significant insider sale at the company.
Financial MarketsLife Sciences
- Published
- 25 Aug 2026 20:42
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.0d old
- Duplicates
- 1 consolidated
#27—Not directional
Stock TitanDirect company coverageStored article
Revolution Medicines (RVMD) CEO trades stock under preset 10b5-1 plan
Revolution Medicines (RVMD) CEO Mark A. Goldsmith exercised options for 80,000 shares and subsequently sold 86,000 shares of common stock, including through revocable trusts, under a pre-arranged Rule 10b5-1 trading plan adopted on May 22, 2026. The sales occurred at weighted average prices between $206.78 and $212.74, while the options were exercised at $4.73 per share. Goldsmith's reported holdings still include 182,938 restricted stock units.
Financial MarketsLife Sciences
- Published
- 25 Aug 2026 20:11
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.0d old
- Duplicates
- 1 consolidated
#28—Not directional
Stock TitanDirect company coverageStored article
Revolution Medicines (RVMD) GC trades 56K shares via 10b5-1 plan
Revolution Medicines' General Counsel, Jeff Cislini, exercised stock options for 56,280 shares and subsequently sold 56,894 shares of common stock on August 21, 2026. These transactions, executed under a Rule 10b5-1 trading plan, involved sales at weighted average prices ranging from approximately $206.76 to $212.74 per share. Cislini still holds 43,514 restricted stock units after these transactions.
FinanceFinancial MarketsLife Sciences
- Published
- 25 Aug 2026 20:11
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.0d old
- Duplicates
- 1 consolidated
#29—Not directional
finance.yahoo.comDirect company coverageStored article
Top Biopharma Analyst Sees Biotech M&A Market Reopening After a Long Freeze
Quick Read Moderna and Merck's cancer vaccine cut melanoma recurrence risk 49%, sending MRNA up 177% on readout day and 392% year to date. Revolution Medicines' daraxonrasib nearly doubled pancreatic cancer survival versus chemo, with RVMD surging 163% year to date on a $45 billion market cap. AbbVie announced a $10.9 billion Apogee deal and still pledged more M&A capacity as Humira sales collapsed 36% to $756 million. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Merck didn't make the cut. Grab the names FREE today. Barclays' Emily Field, Head of U.S. Bi
BiotechCancer VaccineM AOncologyPharma
- Published
- 24 Aug 2026 12:59
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.3d old
- Duplicates
- 1 consolidated
#3011Tone
vinanet.vnDirect company coverageScored from headline
Revolution (RVMD) Q2 2026 Earnings: The Available Earnings Metric Delivers a Miss in the Latest Session; Market Reaction: Shares Fall 1.07% - Profit Warning Alert
- Published
- 24 Aug 2026 07:35
- News subject
- Earnings
- Why this score
- Missed expectations, Profit Warning, Negative market reaction, Large negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- High · 69/100
- 30-day weight
- 4.5% of the score · 14.5d old
- Duplicates
- 1 consolidated
Earlier company news
RVMD news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Aug
08
2026
Simply Wall StreetArchivedNeutral tone
Why Revolution Medicines (RVMD) Is Up 9.4% After Mounting Losses And Surging Daraxonrasib Demand – And What's Next
Revolution Medicines (RVMD) reported a significant net loss in Q2 2026, yet its stock rose by 9.4% due to advancing daraxonrasib through FDA review for metastatic pancreatic cancer and high compassionate use demand. Over 2,000 patients have received daraxonrasib, indicating strong real-world interest, and the company has a substantial cash balance to support its pipeline. The focus now is on potential FDA approval, which could reshape its investment narrative despite ongoing losses and high cash burn.
EarningsFinancial MarketsLife SciencesTechnology
- Published
- 8 Aug 2026 20:39
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 3 consolidated
Aug
07
2026
The Business JournalsArchivedNeutral tone
'We're excited and ready to go': Fast-growing Revolution Medicines preps potential launch of blockbuster pancreatic cancer drug
Revolution Medicines is preparing for the potential launch of its pancreatic cancer drug, daraxonrasib. The Redwood City-based company, led by CEO Mark Goldsmith, boasts a substantial financial reserve of $3.9 billion in cash and equivalents, positioning it strongly among mid-size biotechs for this significant development.
Life Sciences
- Published
- 7 Aug 2026 21:10
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
07
2026
Market sourceArchivedNeutral tone
Revolution Medicines, Inc. (RVMD) interactive stock chart
- Published
- 7 Aug 2026 17:02
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
06
2026
TradingViewArchivedPositive tone
Revolution Medicines, Inc. Stock 12‑Month Price Target Raised to $216.4, Implies 10% Upside
Revolution Medicines, Inc. (RVMD) has seen its average price target raised from $207.16 to $216.4 by 20 analysts, with forecasts ranging from $151 to $263 per share. This updated target suggests a potential 10% upside based on the Aug. 5 closing price. The consensus rating for RVMD remains "Buy" among 21 covering analysts.
Financial MarketsLife Sciences
- Published
- 6 Aug 2026 21:10
- Catalyst
- Analyst action
- Coverage
- Direct company
- Duplicates
- 2 consolidated
Aug
06
2026
TradingViewArchivedNegative tone
RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View
Revolution Medicines RVMD reported an adjusted loss of $2.34 per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of $1.93. The adjusted figure excluded a non-cash charge of $151 million tied to a change in the fair value of warrants assumed through the EQRx acquisition, which closed in 2023. Including this item, the reported loss was $3.06 per share. The company had incurred a loss of $1.31 per share in the year-ago quarter. Currently, RVMD does not have any approved products in its portfolio. It has yet to generate revenues. Shares of the company fell in
BiotechClinical TrialsEarningsEarnings ResultsFda ApprovalFourth Quarter
- Published
- 6 Aug 2026 19:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
06
2026
MarketBeatArchivedNeutral tone
Quantinno Capital Management LP Boosts Stake in Revolution Medicines, Inc. $RVMD
Quantinno Capital Management LP significantly increased its stake in Revolution Medicines (RVMD) by 97.6% in the first quarter, now owning 63,360 shares valued at $6.16 million. Despite the company reporting a wider-than-expected quarterly loss of $3.06 per share, institutional investors hold 94.34% of the stock, and analysts maintain a "Moderate Buy" rating with an average price target of $144.67. Insider selling also occurred, with executives selling shares worth approximately $21.5 million during the quarter.
EarningsFinanceFinancial MarketsLife Sciences
- Published
- 6 Aug 2026 09:41
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
06
2026
MarketBeatArchivedNeutral tone
Revolution Medicines (NASDAQ:RVMD) Announces Earnings Results
- Published
- 6 Aug 2026 05:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
06
2026
Investing.comArchivedPositive tone
Earnings call transcript: Revolution Medicines lifts spending outlook in Q2 2026
Revolution Medicines ended Q2 2026 with $3.9 billion in cash and investments and increased its 2026 spending forecast to $2.1 billion to $2.2 billion to advance late-stage oncology programs and prepare for a potential first product launch. The company's lead drug, daraxonrasib, cleared a key regulatory hurdle with the FDA accepting its NDA for pancreatic cancer review, and commercial infrastructure is largely in place for a U.S. launch. Despite rising net losses due to increased R&D and administrative expenses, the stock remains near its 52-week high, indicating investor focus on the pipeline and future commercialization.
EarningsLife Sciences
- Published
- 6 Aug 2026 02:13
- Catalyst
- Guidance
- Coverage
- Direct company
- Duplicates
- 2 consolidated
Aug
05
2026
MoomooArchivedNegative tone
Revolution Medicines Q2 Net Loss Widens
Revolution Medicines reported a significant widening of its net loss in Q2, increasing to $111.4 million from $70.8 million year-over-year, largely due to increased research and development expenses. Despite the loss, the company exceeded revenue expectations with $9.3 million, up from $2.1 million in the prior year, driven by collaboration revenue. Revolution Medicines ended the quarter with $910.6 million in cash, cash equivalents, and marketable securities.
BiotechEarningsFinancial ResultsFourth QuarterLife SciencesPrice Target
- Published
- 5 Aug 2026 23:13
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
05
2026
Investing.comArchivedNegative tone
Revolution Medicines falls on second quarter earnings miss
Revolution Medicines (NASDAQ:RVMD) reported a significant earnings miss for the second quarter, with a loss of -$3.06 per share against an estimated -$1.96. The net loss for the quarter reached $644.4 million, impacted by a non-cash charge related to an acquisition. Despite the financial miss, the company highlighted the progress of its drug daraxonrasib, including the FDA's acceptance of its New Drug Application for metastatic pancreatic cancer.
EarningsFinancial MarketsLife Sciences
- Published
- 5 Aug 2026 22:13
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
05
2026
GlobeNewswireArchivedNeutral tone
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Revolution Medicines announced its Q2 2026 financial results and provided an update on corporate progress, highlighting the FDA's acceptance of daraxonrasib's New Drug Application for metastatic pancreatic cancer and the rapid implementation of an Expanded Access Program. The company also reported encouraging new combination data for daraxonrasib, zoldonrasib, and elironrasib in lung cancer, supporting future registrational studies, and updated its full-year operating expense guidance.
BiotechClinical TrialsEarningsFda ApprovalFinanceFinancial Results
- Published
- 5 Aug 2026 21:41
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
05
2026
Investing.com CanadaArchivedNeutral tone
Revolution Medicines stock hits all-time high of 195.48 USD By Investing.com
Revolution Medicines Inc. (RVMD) has reached an all-time stock high of $195.48, reflecting significant investor confidence with a 1-year price return of 403.93%. Despite an InvestingPro analysis suggesting the stock is overvalued, analysts from UBS, Mizuho, Wedbush, and Truist Securities have raised price targets or maintained "Buy" ratings, citing promising clinical data and regulatory progress. The company's market capitalization has grown to $41.14 billion, indicating strong market belief in its biotechnology advancements.
EarningsFinancial MarketsLife Sciences
- Published
- 5 Aug 2026 14:45
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
05
2026
Stock TitanArchivedNegative tone
Revolution Medicines (Nasdaq: RVMD) widens loss as R&D spend and financing surge
- Published
- 5 Aug 2026 08:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
05
2026
24/7 Wall St.ArchivedNeutral tone
Revolution Medicines RVMD Q2 2026: FDA Acceptance and a $151M Charge Explained
- Published
- 5 Aug 2026 08:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
05
2026
MarketBeatArchivedNeutral tone
Revolution Medicines (NASDAQ:RVMD) Announces Earnings Results
- Published
- 5 Aug 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
05
2026
MarketBeatArchivedNeutral tone
Revolution Medicines (RVMD) Earnings Date and Reports 2026
- Published
- 5 Aug 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
04
2026
finance.yahoo.comArchivedPositive tone
Could Revolution Medicines (RVMD) Become a $20 Billion Cancer Drug Story?
Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% on an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong stock selection in pharmaceuticals, biotechnology, health care equipment, and life sciences tools and services supported the Fu
BiotechClinical TrialsFda ApprovalPharmaceuticals
- Published
- 4 Aug 2026 14:19
- Catalyst
- Regulatory and legal
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
03
2026
nasdaq.comArchivedPositive tone
Billionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy?
Key Points Druckenmiller initiated a new stake in Revolution Medicines in Q1. The biotech stock has skyrocketed on excitement about its lead cancer candidate, daraxonrasib. Revolution Medicine's valuation makes the stock a riskier proposition now.10 stocks we like better than Revolution Medicines › Stanley Druckenmiller isn't afraid to take risks. His boldness has paid off through the years. Druckenmiller's net worth stands at $7.8 billion. His Duquesne Family Office has roughly $3 billion in assets under management. One notable example of Druckenmiller's risk-taking is his investments in clin
BiotechCancer TherapyClinical TrialsFda ApprovalMarketsShare Price
- Published
- 3 Aug 2026 09:12
- Catalyst
- Deals and strategy
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
02
2026
Simply Wall StArchivedNeutral tone
Is Revolution Medicines (RVMD) Fully Valued Following Its FDA Filing Win?
Revolution Medicines (RVMD) has seen significant stock price appreciation following the FDA's acceptance of its New Drug Application for daraxonrasib. Despite a 137.32% year-to-date increase, Simply Wall St's analysis suggests RVMD is 8.2% undervalued, with a fair value pegged at $204.38 based on its strong pipeline of oncology treatments. However, the company still faces risks associated with high cash burn and the potential for trial delays.
EarningsFinancial MarketsLife Sciences
- Published
- 2 Aug 2026 23:11
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 2 consolidated
Aug
02
2026
nasdaq.comArchivedPositive tone
Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock
Key Points Druckenmiller bought 316,000 shares of Revolution Medicines in the first quarter. The company doesn't generate revenue yet and lost $453 million in the first quarter. Revolution uses RAS proteins to treat aggressive cancers.10 stocks we like better than Revolution Medicines › Shares of biotechnology company Revolution Medicines(NASDAQ: RVMD) have surged more than 134% so far this year. Billionaire investor Stanley Druckenmiller's Duquesne Family Office drew attention to the stock by buying 316,000 shares of Revolution in the first quarter. The move has paid off for Druckenmiller, as
BiotechCancer TherapyClinical TrialsFda ApprovalM AMarkets
- Published
- 2 Aug 2026 21:05
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 2 consolidated
Aug
02
2026
The Motley FoolArchivedPositive tone
Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock
Key Points Druckenmiller bought 316,000 shares of Revolution Medicines in the first quarter. The company doesn't generate revenue yet and lost $453 million in the first quarter. Revolution uses RAS proteins to treat aggressive cancers.10 stocks we like better than Revolution Medicines › Shares of biotechnology company Revolution Medicines(NASDAQ: RVMD) have surged more than 134% so far this year. Billionaire investor Stanley Druckenmiller's Duquesne Family Office drew attention to the stock by buying 316,000 shares of Revolution in the first quarter. The move has paid off for Druckenmiller, as
BiotechCancer TherapyClinical TrialsFda ApprovalM AMarkets
- Published
- 2 Aug 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 3 consolidated
Aug
01
2026
TradingViewArchivedNeutral tone
Price to earnings forward of Revolution Medicines, Inc. – BOATS:RVMDW
The article focuses on the "Price to earnings forward" for Revolution Medicines, Inc. (RVMDW), listed on the Blue Ocean Alternative Trade System (BOATS). It presents financial information related to RVMDW, including market status and data provided by ICE Data Services and FactSet. The page indicates that the market was closed with no trades.
EarningsFinanceFinancial MarketsLife Sciences
- Published
- 1 Aug 2026 12:41
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
01
2026
TradingViewArchivedNeutral tone
Revolution Medicines, Inc. Revenue Breakdown – NASDAQ:RVMD
This page provides financial overview information for Revolution Medicines, Inc. (NASDAQ: RVMD) on TradingView. It indicates that the market is currently closed with no trades and offers access to various financial data points such as statements, statistics, dividends, earnings, and segment performance.
EarningsFinancial MarketsLife Sciences
- Published
- 1 Aug 2026 05:39
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
31
2026
Simply Wall StArchivedNeutral tone
FDA Priority Review For Daraxonrasib Might Change The Case For Investing In Revolution Medicines (RVMD)
Revolution Medicines (RVMD) has received FDA priority review for its New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for metastatic pancreatic cancer. This decision, backed by positive Phase 3 data, is a significant catalyst for the company, potentially reshaping its investment narrative despite ongoing losses and high spending. Investors will be monitoring Q2 2026 earnings for insights into operational expenses versus pipeline progress, with daraxonrasib's success being key to future financial performance.
EarningsFinancial MarketsLife Sciences
- Published
- 31 Jul 2026 16:26
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
31
2026
https://hrtoday.in/ArchivedNeutral tone
Sandra Heller Joins Revolution Medicines as Vice President & General Manager, Canada
Revolution Medicines has appointed Sandra Heller as Vice President & General Manager for Canada, enhancing its commercial leadership in oncology. Heller brings over 25 years of experience from companies like Astellas Pharma Canada, Seagen, Gilead Sciences, and Roche, and will lead Canadian operations, commercial strategy, and market expansion. Her appointment underscores Revolution Medicines' commitment to delivering innovative targeted therapies, particularly for RAS-addicted cancers, to patients in Canada.
Life Sciences
- Published
- 31 Jul 2026 16:10
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
31
2026
TradingViewArchivedNeutral tone
Enterprise value to EBIT forward of Revolution Medicines, Inc. – NASDAQ:RVMDW
This article focuses on the enterprise value to EBIT forward of Revolution Medicines, Inc. (NASDAQ: RVMDW). The content primarily serves as a financial data point or a placeholder within the TradingView platform for the company's financial metrics.
Financial MarketsLife Sciences
- Published
- 31 Jul 2026 13:39
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
30
2026
Revelio LabsArchivedNeutral tone
Revolution Medicines Number of Employees 2026 | Employee Count & Headcount Data
Revolution Medicines, Inc. (NASDAQ: RVMD) had approximately 1,025 employees worldwide as of March 2026, marking an 83.5% growth since 2023. The company is actively hiring, with 384 active job postings in 2026, and its workforce is primarily concentrated in the United States. Employee sentiment is neutral but improving, and the average salary is $216,810.
Life Sciences
- Published
- 30 Jul 2026 17:39
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
30
2026
ChartMillArchivedPositive tone
Revolution Medicines (NASDAQ:RVMD) Flashes Strong Technical Breakout Setup
Revolution Medicines (NASDAQ:RVMD) is showing a strong technical breakout setup, scoring 9 out of 10 on both ChartMill's Technical Rating and Setup Quality Rating. This indicates a sustained positive trend with the stock trading well above its moving averages and near its 52-week high, coupled with a tight consolidation pattern resembling a bull flag. The article suggests RVMD is a textbook candidate for a breakout trade, with potential for a new leg higher if it breaks above the resistance zone around $192.62–$192.63.
Financial MarketsLife Sciences
- Published
- 30 Jul 2026 13:40
- Catalyst
- Analyst action
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
30
2026
Stock TitanArchivedNeutral tone
BlackRock (NYSE: BLK) reports 5.7% ownership in Revolution Medicines (RVMD)
BlackRock, Inc. has disclosed a 5.7% beneficial ownership stake in Revolution Medicines (RVMD), amounting to 12,201,395 common shares. This ownership gives BlackRock sole voting power over 11,508,777 shares and sole dispositive power over all 12,201,395 shares. The filing, a Schedule 13G, indicates that these holdings are managed by specific BlackRock business units for various underlying clients, with no single client holding more than five percent of RVMD's outstanding common shares.
FinanceFinancial MarketsLife Sciences
- Published
- 30 Jul 2026 05:36
- Catalyst
- Deals and strategy
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
29
2026
nasdaq.comArchivedNeutral tone
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now
Key Points Revolution Medicines has a promising cancer drug in development. Even with this medicine's prospects, the stock's valuation looks too frothy. 10 stocks we like better than Revolution Medicines › Shares of Revolution Medicines(NASDAQ: RVMD), a clinical-stage drugmaker, have gained 132% this year, easily outpacing the returns of leading pharmaceutical companies such as Eli Lilly(NYSE: LLY), Johnson & Johnson(NYSE: JNJ), and AbbVie(NYSE: ABBV). The question now is whether Revolution Medicines can keep the momentum going. Let's find out whether there is more upside ahead. The valuation
BiotechClinical TrialsMarketsOncologyPharmaRisk Reward
- Published
- 29 Jul 2026 22:20
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 2 consolidated
Provider matches checked
Provider mentions not used in the score
A news provider linked these stories to RVMD, but the headline and available text are not mainly about Revolution Medicines Inc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of RVMD sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.